Details for New Drug Application (NDA): 214408
NDA 214408 describes PEMETREXED DISODIUM, which is a drug marketed by Accord Hlthcare, Amneal, Apotex, Baxter Hlthcare Corp, Biocon Pharma, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hetero Labs Ltd Vi, Hospira, Jiangsu Hansoh Pharm, Meitheal, Nang Kuang Pharm Co, Pharmobedient, Prinston Inc, Qilu Pharm Hainan, Somerset Theraps Llc, Zydus Pharms, and Sandoz, and is included in twenty-three NDAs. It is available from sixteen suppliers. Additional details are available on the PEMETREXED DISODIUM profile page.
The generic ingredient in PEMETREXED DISODIUM is pemetrexed disodium. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.
The generic ingredient in PEMETREXED DISODIUM is pemetrexed disodium. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.
Summary for 214408
| Tradename: | PEMETREXED DISODIUM |
| Applicant: | Accord Hlthcare |
| Ingredient: | pemetrexed disodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 214408
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 100MG BASE/4ML (EQ 25MG BASE/ML) | ||||
| Approval Date: | Jul 19, 2022 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 500MG BASE/20ML (EQ 25MG BASE/ML) | ||||
| Approval Date: | Jul 19, 2022 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 850MG BASE/34ML (EQ 25MG BASE/ML) | ||||
| Approval Date: | Jul 19, 2022 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
